Fundraising Fox
Focal Therapeutics
acquired by HologicAliso Viejo, US · 2 known investors
Find your way into Focal Therapeutics
Sign up to see every warm intro you have to Focal Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Focal Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Hologic, Inc. October 2018 · $125M ($125 million (Hologic SEC filings cite ~$120.1M initial purchase price)) · source ↗
Focal Rx develops bioabsorbable medical devices, specifically the BioZorb 3D Bioabsorbable Marker, for clinical and surgical applications. The company operates in the medical device sector serving healthcare providers and patients.
Founders & leadership
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$11.7M disclosed across 3 rounds · 2013–2016
▶$48.9KraisedJan 2017 · 2 investors · Other Health CareRule 506(b)
- Steven NaberExecutive Officer
- Robert BrownellDirector
- Gail S. LebovicExecutive Officer, Director
- Steven GexExecutive Officer, Director
- Sharon StevensonDirector
- George D. HermannExecutive Officer, Director
- Offering amount
- $48.9K
- Amount sold
- $48.9K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedMar 2016 · 28 investors · Other Health CareRule 506(b)
- Gail S LebovicExecutive Officer, Director
- George D HermannExecutive Officer
- Robert BrownellDirector
- Steven GexExecutive Officer, Director
- Sharon StevensonDirector
- Steven NaberExecutive Officer
- Offering amount
- $5M
- Amount sold
- $3.8M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedSep 2014 · 22 investors · Other Health CareRule 506(b)
- Steven GexExecutive Officer, Director
- Robert BrownellDirector
- George D HermannExecutive Officer, Director
- Steven NaberExecutive Officer
- Sharon StevensonDirector
- Gail S LebovicDirector
- Offering amount
- $10.1M
- Amount sold
- $7.8M
- First sale
- Aug 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Focal Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Focal Therapeutics do?
- Focal Rx develops bioabsorbable medical devices, specifically the BioZorb 3D Bioabsorbable Marker, for clinical and surgical applications. The company operates in the medical device sector serving healthcare providers and patients.
- Who are Focal Therapeutics's investors?
- Focal Therapeutics's investors include Emergent Medical Partners, LLP, Okapi Venture Capital.
- How much funding has Focal Therapeutics raised?
- Focal Therapeutics has disclosed $11.7M raised across 3 rounds.
- Who acquired Focal Therapeutics?
- Focal Therapeutics was acquired by Hologic.
- Where is Focal Therapeutics headquartered?
- Focal Therapeutics is headquartered in Aliso Viejo, US.